China has issued a patent for Neovacs’ interferon alpha (IFNα) vaccine for diseases characterized by over-expression of the cytokine IFNα, including lupus, dermatomyositis and type 1 diabetes. The patent, together with others Neovacs has obtained, give the company global protection for the vaccine until at least 2032. Neovacs’ technology targets…
News
Years of persistent detective work allowed researchers to discover a gene mutation that increases the risk of systemic lupus erythematosus and other autoimmune diseases Interestingly, the gene is also associated with lower production of reactive oxygen species. These chemicals, which contain oxygen, play roles in cell signaling and homeostasis, or…
The Lupus Foundation of America is accepting funding applications from students and researchers working in lupus research. “Lupus is a complex disease that presents challenges that can only be overcome by a robust public and private medical research effort,” Sandra C. Raymond, the foundation’s president and CEO, said in a news…
A patient treated with Benlysta (belimumab), an FDA-approved treatment for active systemic lupus erythematosus (SLE), developed central nervous system nocardiosis, according to a recent case report. The report, “A Case Of Central Nervous System Nocardiosis In A Patient With Lupus Treated With Belimumab,” was published in the European…
The Phase 2b clinical trial evaluating interferon-alpha (IFNα) Kinoid, Neovacs’ immunotherapy candidate for the treatment of systemic lupus erythematosus (SLE), received a positive interim data review from the Independent Data and Safety Monitoring Board (IDSMB) overseeing the study. The randomized, multicenter and international clinical trial (NCT02665364) is evaluating the biological…
Treatment with azathioprine, a drug commonly used in autoimmune diseases like systemic lupus erythematosus (SLE), may considerably increase a person’s risk for serious bone marrow diseases known as myeloid neoplasms, according to a study from the Mayo Clinic. Researchers reported that people using azathioprine could be at seven times higher risk of…
Patients with systemic lupus erythematosus (SLE) had lower disease activity when they took the investigational treatment anifrolumab along with standard medications, according to a recently completed Phase 2b clinical trial (NCT01438489). Noting the treatment’s potential to target several organs and ease the disease’s symptoms, researchers called the trial “the…
Novel genetic variations known as single nucleotide polymorphisms (SNPs) are associated with a higher incidence of systemic lupus erythematosus (SLE) in Asians, research shows. The study, “Evaluation of 10 SLE susceptibility loci in Asian populations, which were initially identified in European populations,” was published in the journal Scientific Reports. A…
Systemic lupus erythematosus (SLE) patients are more likely to have a chronic hepatitis C virus (HCV) infection than those without lupus, according to a study. The research, “Chronic hepatitis C viral infection among SLE patients: the significance of coexistence,” was published in the journal Immunologic Research.
Worldwide Clinical Trials has been chosen to conduct Aurinia Pharmaceuticals’ Phase 3 trial, called AURORA, evaluating voclosporin as a potential treatment for active lupus nephritis (LN). The trial is expected to begin by mid-year. The company plans to use the study’s results to support a New Drug…
Recent Posts
- To my ‘forever nurse,’ who finally gave me my diagnosis of lupus
- New analyses show Benlysta may aid flare control, kidney health
- Can art therapy help lupus patients improve cognitive function?
- With chronic illness, checking in means asking, ‘How ya really doin’?’
- FDA approves Gazyva as lupus nephritis treatment